Payment overview · 2025
General Payments
$6,408.18
195 reported records · 34 companies
Healthcare provider profile · identity verified
Rodolfo Trejo, MD
Allopathic & Osteopathic Physicians|Family Medicine · ATLANTIS, FL · NPI 1750335584
Verified facts
What the public records show
CMS Open Payments records show Rodolfo Trejo, MD received $6,408.18 in general payments during 2025 across 195 reported records.
AstraZeneca Pharmaceuticals LP accounted for 21.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Otezla, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $1,391.36 | 21.7% | 25 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $694.36 | 10.8% | 25 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $596.62 | 9.3% | 19 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $297.51 | 4.6% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $293.48 | 4.6% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $283.63 | 4.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $229.55 | 3.6% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $200.70 | 3.1% | 9 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $191.73 | 3.0% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $189.45 | 3.0% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $170.16 | 2.7% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $167.92 | 2.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $157.15 | 2.5% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $143.90 | 2.2% | 6 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $135.24 | 2.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $129.80 | 2.0% | 5 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $124.99 | 1.9% | 1 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $124.97 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $106.86 | 1.7% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $99.68 | 1.6% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $96.08 | 1.5% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $81.73 | 1.3% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $78.20 | 1.2% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $57.74 | 0.9% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $55.76 | 0.9% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.07 | 0.8% | 3 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $52.19 | 0.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $50.31 | 0.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.37 | 0.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $36.17 | 0.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.47 | 0.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.19 | 0.3% | 1 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.14 | 0.3% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $15.70 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $6,408.18 | 195 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $803.00 | 18 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $694.36 | 25 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $375.71 | 12 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $293.48 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $283.63 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $243.45 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $240.23 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $229.55 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $220.87 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $212.03 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $200.70 | 9 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $191.73 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $170.16 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $167.92 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $163.72 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $143.90 | 6 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $139.96 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $135.24 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $129.53 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Opzelura Normalized: opzelura |
Drug | Incyte Corporation | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $122.99 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $112.85 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $112.85 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $106.86 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $99.68 | 5 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $97.76 | 3 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $95.88 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $87.04 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $81.73 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $78.12 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $59.92 | 4 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $55.76 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $53.07 | 3 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $52.19 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $50.31 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $44.30 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.37 | 2 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $37.23 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $36.17 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $32.04 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.14 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.47 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.91 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $15.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 250 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 114 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 74 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 76 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 88 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 70 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 79 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 87 | exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 56 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
76 | 21 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 16 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
64 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
114 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
145 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
53 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
145 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
250 | 48 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 617 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 586 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 576 | 153 |
| Quetiapine Fumarate | Quetiapine Fumarate | 562 | 52 |
| Alprazolam | Alprazolam | 479 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 449 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 356 | 83 |
| Metformin Hcl | Metformin Hcl | 350 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 348 | 86 |
| Furosemide | Furosemide | 347 | 85 |
| Potassium Chloride | Potassium Chloride | 285 | 68 |
| Montelukast Sodium | Montelukast Sodium | 266 | 77 |
| Meloxicam | Meloxicam | 263 | 77 |
| Trazodone Hcl | Trazodone Hcl | 259 | 46 |
| Eliquis | Apixaban | 250 | 48 |
| Gabapentin | Gabapentin | 248 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 239 | 80 |
| Losartan Potassium | Losartan Potassium | 235 | 45 |
| Lorazepam | Lorazepam | 230 | 38 |
| Omeprazole | Omeprazole | 230 | 55 |
| Donepezil Hcl | Donepezil Hcl | 219 | 30 |
| Amitriptyline Hcl | Amitriptyline Hcl | 210 | 56 |
| Lisinopril | Lisinopril | 210 | 62 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 206 | 54 |
| Memantine Hcl | Memantine Hcl | 202 | 31 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 187 | 31 |
| Carvedilol | Carvedilol | 184 | 50 |
| Clonazepam | Clonazepam | 183 | 34 |
| Diazepam | Diazepam | 179 | 28 |
| Mirtazapine | Mirtazapine | 177 | 45 |
| Abilify Maintena | Aripiprazole | 145 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 139 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 137 | 49 |
| Bupropion Xl | Bupropion Hcl | 135 | 42 |
| Prednisone | Prednisone | 134 | 84 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 31 |
| Morphine Sulfate Er | Morphine Sulfate | 132 | 17 |
| Ibuprofen | Ibuprofen | 129 | 42 |
| Azithromycin | Azithromycin | 126 | 107 |
| Oxycodone Hcl | Oxycodone Hcl | 125 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 120 | 37 |
| Megestrol Acetate | Megestrol Acetate | 119 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 118 | 22 |
| Sertraline Hcl | Sertraline Hcl | 117 | 23 |
| Simvastatin | Simvastatin | 117 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 115 | 36 |
| Farxiga | Dapagliflozin Propanediol | 114 | 23 |
| Cefuroxime | Cefuroxime Axetil | 112 | 87 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 107 | 30 |
| Famotidine | Famotidine | 106 | 25 |
| Glimepiride | Glimepiride | 105 | 30 |
| Methocarbamol | Methocarbamol | 101 | 44 |
| Xarelto | Rivaroxaban | 100 | 23 |
| Mupirocin | Mupirocin | 98 | 53 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 98 | 62 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 16 |
| Buspirone Hcl | Buspirone Hcl | 95 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 26 |
| Ozempic | Semaglutide | 88 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 87 | 20 |
| Ciclopirox | Ciclopirox Olamine | 85 | 43 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 84 | 14 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 83 | 75 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 31 |
| Enalapril Maleate | Enalapril Maleate | 80 | 16 |
| Sucralfate | Sucralfate | 80 | 21 |
| Rybelsus | Semaglutide | 79 | 14 |
| Ketoconazole | Ketoconazole | 76 | 15 |
| Linzess | Linaclotide | 76 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 54 |
| Jardiance | Empagliflozin | 74 | 19 |
| Nystatin | Nystatin | 74 | 27 |
| Pregabalin | Pregabalin | 74 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 73 | 58 |
| Levetiracetam | Levetiracetam | 72 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 17 |
| Rexulti | Brexpiprazole | 70 | 15 |
| Valacyclovir | Valacyclovir Hcl | 70 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 68 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 65 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 20 |
| Myrbetriq | Mirabegron | 64 | 12 |
| Risperidone | Risperidone | 63 | suppressed |
| Temazepam | Temazepam | 63 | 16 |
| Allopurinol | Allopurinol | 62 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 62 | 45 |
| Meclizine Hcl | Meclizine Hcl | 61 | 18 |
| Tramadol Hcl | Tramadol Hcl | 61 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 60 | 21 |
| Metformin Hcl Er | Metformin Hcl | 60 | 16 |
| Vraylar | Cariprazine Hcl | 56 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | 11 |
| Topiramate | Topiramate | 55 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 54 | 28 |
| Finasteride | Finasteride | 54 | 13 |
| Latanoprost | Latanoprost | 54 | suppressed |
| Entresto | Sacubitril/Valsartan | 53 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | suppressed |
| Glipizide | Glipizide | 53 | 13 |
| Levofloxacin | Levofloxacin | 53 | 47 |
| Diltiazem Hcl | Diltiazem Hcl | 52 | suppressed |
| Olanzapine | Olanzapine | 52 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 51 | 12 |
| Lovastatin | Lovastatin | 49 | suppressed |
| Bumetanide | Bumetanide | 48 | 14 |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 45 | suppressed |
| Valsartan | Valsartan | 45 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 44 | 18 |
| Doxepin Hcl | Doxepin Hcl | 44 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 44 | 14 |
| Fluconazole | Fluconazole | 43 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 11 |
| Testosterone | Testosterone | 42 | 12 |
| Baclofen | Baclofen | 41 | 15 |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 40 | 16 |
| Hydrocortisone | Hydrocortisone | 39 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 39 | 16 |
| Tradjenta | Linagliptin | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 17 |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Lactulose | Lactulose | 37 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 37 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 37 | 19 |
| Ondansetron Odt | Ondansetron | 37 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 35 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 27 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Ofloxacin | Ofloxacin | 33 | 31 |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 11 |
| Glycopyrrolate | Glycopyrrolate | 31 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Naproxen | Naproxen | 30 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | 15 |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Metronidazole | Metronidazole | 29 | 24 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 28 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Prolia | Denosumab | 28 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 27 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 26 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Anastrozole | Anastrozole | 24 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 24 | suppressed |
| Lumigan | Bimatoprost | 24 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Trandolapril | Trandolapril | 21 | suppressed |
| Unithroid | Levothyroxine Sodium | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Enbrel | Etanercept | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | suppressed |
| Humira(Cf) Pen | Adalimumab | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Gemtesa | Vibegron | 16 | suppressed |
| Otezla | Apremilast | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 14 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Naproxen Sodium Er | Naproxen Sodium | 13 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Nexletol | Bempedoic Acid | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clarithromycin | Clarithromycin | 11 | 11 |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 11 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $6,408.18 · 195 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APRETUDE, AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EOHILIA, EVENITY, FANAPT, FARXIGA, FASENRA, FREESTYLE LIBRE 3, GEMTESA, GVOKE HYPOPEN, IBSRELA, INGREZZA, JARDIANCE, KISUNLA, Kerendia, Korlym, LEQVIO, LINZESS, MYFEMBREE, NURTEC ODT, OTEZLA, Ohtuvayre, Opzelura, Ozempic, QULIPTA, Quviviq, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, Tlando, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZAVZPRET, ZORYVE | 26 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error